Barclays Boosts Argenx (ARGX) PT to EUR 680 After Strong Q1 2025 Performance

On June 4, Barclays raised its price target for Argenx (NASDAQ:ARGX) from EUR 650 to EUR 680, while keeping an Overweight rating on the company’s shares. This sentiment indicated the firm’s continued confidence in the company’s performance.

Barclays Boosts Argenx (ARGX) PT to EUR 680 Amid Strong Q1 2025 Performance

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

The company reported a total operating income of $807 million in Q1 2025. Product net sales reached $790 million, which represented 99% growth year-over-year. Regional sales breakdown showed $681 million from the US, $32 million from Japan, $57 million from the rest of the world, and $20 million from product supply to Zai Lab in China. Overall, sequential growth was 7%, with the US experiencing 5% growth.

Argenx successfully launched a pre-filled syringe for VYVGART in the US and Germany, and this is expected to enhance patient access and convenience. The company is also on track to progress 4 Investigational New Drug/IND applications into clinical trials this year, with ARGX-109 and ARGX-213 already in Phase 1 studies. However, the company experienced typical Q1 seasonality, which impacted growth due to benefit reverification for patients.

Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.

While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.